AB Science Continues Masitinib Development
AB Science is advancing the clinical development of masitinib for conditions including neurological disorders like multiple sclerosis and ALS. The company provides updates on its research progress.
AB Science, a biopharmaceutical company, is continuing its work on the clinical development of masitinib, a tyrosine kinase inhibitor, for various diseases. The company's primary focus remains on investigating the efficacy and safety of masitinib in treating neurological conditions such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).
The company's research pipeline includes masitinib for several indications. AB Science has published information regarding ongoing studies and the potential of masitinib in conditions like MS, ALS, Alzheimer's disease, and sickle cell disease. These studies aim to evaluate the drug's impact on disease progression and patient symptoms.
AB Science actively communicates its research findings and development milestones through its press releases and investor relations channels. The company's website provides access to information regarding its clinical programs and scientific publications. Updates on regulatory submissions and trial outcomes are a key part of their communication strategy.
The company's strategy involves targeting significant unmet medical needs. AB Science states its commitment to advancing masitinib through clinical trials with the goal of making it available to patients who could benefit from this therapeutic option.